Sex differences in response to bDMARDs in RA, PsA & SpA? YES. Data from BIOREG- 477 RA, 150 PsA, 312 SpA treated with rap TNFi. Men respond better to TNFi in all groups POS0208 #EULAR2021 @RheumNow @eular_org https://t.co/7FoI3p0qwe

2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU

Deucravacitinib (TYK2i) - phase II trial for PsA ⭐️ACR20, 50, 70 response ⭐️HAQ-DI response ⭐️LEI/SPARCC response ⭐️MDA response Abs#OP0227 #EULAR2021 @RheumNow

Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic ⭐️ACR20, 50,70 response ⭐️significant resolution of enthesitis/dactylitis Abs#OP0228 #EULAR2021 @RheumNow

Latest GRAPPA guidelines for treatment of PsA Abs#OP0229 #EULAR2021 @RheumNow https://t.co/YlHHQsFGC8

Lower ILD incidence in PsA than RA in a large Nordic registry ⭐️ No significant ⬆️ in ILD in those using MTX Abs#OP0222 #EULAR2021 @RheumNow https://t.co/lgGhu1Hmd6

Key points on phenotypes in PsA per Dr. Dafna Gladman: ⭐️Oligoarticular & polyarticular PsA pts have the same burden of dz ⭐️Dactylitis assoc w/ greater dz severity & US synovitis + erosive changes in DMARD-naive early PsA pts #EULAR2021 @RheumNow

#EULAR2021 Gender differences in chronic #arthritis 🙋🙋‍♂️ ▶️ POS1061: The Italian prospective SIRENA study: women do worse at the onset of #psoriaticarthritis 🇮🇹 ▶️ POS0208: The Austrian Registry BIOREG: women showed lower response rates to #TNFi 🇦🇹 > LA https://t.co/JNxrqimp2Y

Dr Deodhar on upadacitinib in axial PsA. Appears to be effective in combined analysis of SELECT-PsA 1 and 2. @RheumNow #EULAR2021 Abstr#0233 https://t.co/fBMWVb3oBd

Israeli study of all cause mortality in PsA vs general population ⭐️no increased mortality in PsA group ⭐️leading causes of death was cancer in both groups ⭐️age, male sex, BMI, socioeconomic status, PsO associated with ⬆️mortality, NOT DMARDs Abs#OP0219 #EULAR2021 @RheumNow

Metabolomic profiling for PsA showed vLDL, triglycerides; apolipoprotein B, glycoprotein acetylene associated with increased CV events… Do you monitor cholesterol levels in your PsA pts? Abs#OP0221 #EULAR2021 @RheumNow

What does this graph represent to you? To me: we have a whole lot of PsA that all work equally well.. It’s time for more personalized approach to PsA treatment! Excellent talk by @DrLauraCoates Abs#OP6937 #EULAR2021 @RheumNow https://t.co/1NKLfmH2y5

Similar efficacy of PsA enthesitis treatment between adalimumab and secukinumab ⭐️mean change and resolution of enthesitis similar ⭐️resolution of equal but ⬇️ in pts with ⬆️ baseline enthesitis activity ⭐️rate of relapse ⬇️ and similar Abs#POS0194 #EULAR2021 @RheumNow https://t.co/uPE4kmotCY

Interesting small study on US assessment of Achilles of PsA vs normal pts after exercise ⭐️significant different of PD signal in PsA group ⭐️5 non-PsA pts still had PD🤔 Would be interesting to further classify differences in PD intensity… Abs#POS1058 #EULAR2021 @RheumNow https://t.co/SLhqq4wgCl